Bicycle Therapeutics

Developing first in class medicines to treat cancer and other debilitating diseases

Bicycle Therapeutics is developing Bicyclic peptides (Bicycles®). Bicycles represent a new therapeutic modality with unique attributes widely applicable across therapy areas. Bicycles are designed to rapidly penetrate tumors, delivering payloads only to where they are needed to minimize systemic toxicology.

For more information, please visit the company's website: www.bicycletherapeutics.com


Life sciences company whose mission is to detect cancer early when it can be cured

GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company's funding includes Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, GV, Illumina, Johnson & Johnson Innovation, Merck, Tencent, Varian Medical Systems, and other financial partners.

For more information, please visit the company's website: www.grail.com


Developing the leading range of first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections

Pulmocide Ltd, is a drug discovery company developing novel compounds designed for inhaled delivery to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis. The Pulmocide team have an extensive track record in the discovery and development of novel inhaled medicines for respiratory indications.

For more information, please visit the company's website: www.pulmocide.com

Renovia, Inc.

Discovering and delivering innovative medical solutions and technology combined with digital health for women with pelvic floor disorders

Renovia, Inc. was formed to better diagnose, treat, and improve women's health through a platform of innovative sensor technology integrated with digital health. This allows precise, cost-effective visualization and treatment of weakened pelvic floor muscles in real time, providing actionable compliance and progress data on women’s pelvic health.

For more information, please visit the company's website: www.renoviainc.com

Axial Biotherapeutics

harnessing the link between the human gut microbiome and
the central nervous system

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders.

For more information, please visit the company's website: www.axialbiotherapeutics.com

Millendo Therapeutics

developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. Our product candidates seek to improve the quality of life for patients with orphan and specialty diseases with limited or no approved treatment options. Our clinical programs are designed to address:

  • Polycystic Ovary Syndrome (PCOS) – the most common endocrine disease in women
  • Adrenocortical Carcinoma (ACC) – a rare endocrine malignancy of the adrenal cortex
  • Congenital Adrenal Hyperplasia (CAH) – a recessive genetic defect of cortisol synthesis
  • Endogenous Cushing’s Syndrome (CS) – a condition resulting from chronic cortisol exces

For more information, please visit the company's website: www.millendo.com

Channel Medsystems

Endometrial ablation device for women

Channel Medsystems was founded to bring innovation to the delivery of women's healthcare. Channel Medsystems is committed to ensuring patients have access to high quality outcomes that can be delivered in the convenience and comfort of their healthcare provider's office. Channel Medsystems' novel cryothermic technology and streamlined delivery system's first application focuses on global endometrial ablation for women with heavy menstrual bleeding. The cryothermic platform at the core of this technology has the potential for multiple future applications. For more information, please visit the company's website: www.channelmedsystems.com.

KalVista Pharmaceuticals

OPHTHALMOLOGY COMPANY FOCUSED ON discovery, development and commercialization of small molecule serine protease inhibitors for diabetic macular edema (DME) and hereditary angioedema (HAE)

KalVista Pharmaceuticals (KalVista) is an ophthalmology company with a primary focus on Diabetic Macular Edema (DME) and deep expertise in the discovery and development of serine protease inhibitors.  KalVista's novel plasma kallikrein inhibitors represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries.  Although VEGF inhibitors (existing treatment) can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options.  Plasma kallikrein inhibitors target a distinct molecular pathway and have the potential to offer those patients an effective treatment option.  KalVista has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications.  KalVista's founders include world experts in diabetic retinopathy, Dr. Lloyd Paul Aiello, Professor of Ophthalmology at Harvard Medical School and Director of the Joslin's Beetham Eye Institute, and Dr. Edward P. Feener, Associate Professor of Medicine at Harvard Medical School and Joslin Diabetes Center.  For more information, please visit the company's website: http://www.kalvista.com/.


Scientifically based, proprietary products that treat sun damaged skin & protect from the damaging effects of the sun, environment and aging

Colorescience is a skincare company that develops and markets scientifically based, proprietary products that treat sun damaged skin, as well as protecting the skin from the damaging effects of the sun, the environment and aging. The products include high-quality, dermatologist-recommended formulations with high SPF. The Colorescience team is led by Mary Fisher who brings more than 25 years of experience in the pharmaceutical and biotechnology industries. Ms. Fisher currently serves as Chief Executive Officer and Director at Colorescience, a former division of SkinMedica, Inc., where she served as Chief Executive Officer from 2008 until 2012, when she led the successful sale of the company to Allergan, Inc. for $375 million. For more information, please visit the company's website http://www.colorescience.com.

Flex Pharma

Novel Treatments for Muscle Cramps and Spasms

Flex Pharma, Inc. (NASDAQ: FLKS) is a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers. Flex Pharma was founded with National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, both serve as board members for the company. For more information, please visit the company's website http://www.flex-pharma.com.

Calithera Biosciences

Developing oncology therapeutics that inhibit pathways critical to tumor growth and survival

Calithera Biosciences, Inc. (NASDAQ: CALA) (Calithera) is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera's lead product candidate, CB-839, an orally bioavailable inhibitor of glutaminase, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. For more information, please visit the company’s website www.calithera.com.


developing drugs that can treat a wide range of serious diseases by modulating mitochondrial function

Mitobridge, Inc. (Mitobridge), formerly known as Mitokyne, is a biopharmaceutical company focused on mitochondria-related drug discovery and development. The company is utilizing its innovative screening platform to identify and develop novel therapeutics that improve mitochondria function and provide treatments for mitochondrial genetic diseases, musculoskeletal and neurodegenerative disorders as well as diseases and conditions of aging. Mitobridge’s scientific founders and advisors include world-renowned leaders in biology and mitochondrial function. For more information about Mitobridge, please visit the company's website at www.mitobridge.com.

PTC Therapeutics

Focused on the discovery, development and commercialization of proprietary small-molecule drugs

PTC Therapeutics, Inc. (PTC) (NASDAQ: PTCT) a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. PTC has received conditional marketing authorization in the European Economic Area for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information, please visit the company’s website www.ptcbio.com.

IlluminOss Medical

minimally invasive solutions for the treatment of bone fractures

IlluminOss Medical (IlluminOss) is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology. This minimally invasive technology allows for fracture fixation using a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The company currently markets and sells its products internationally under CE Mark approval for clinical applications. For more information, please visit the company’s website at www.illuminoss.com.


Improving fertility through science

OvaScience, Inc. (OvaScience) (NASDAQ: OVAS) is a global life sciences company dedicated to improving fertility for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments. Each OvaScience treatment is based on the company's proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. For more information, please visit the company's website at www.ovascience.com.


Novel drugs targeting cancer stem cells

Verastem, Inc. (Verastem) (NASDAQ: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation including focal adhesion kinase (FAK) and PI3K/mTOR. For more information, please visit the company's website at www.verastem.com.

ALNARA Pharmaceuticals

Improving nutritional status and pill burden in patients with pancreatic diseases

Alnara Pharmaceuticals, Inc. (Alnara) is dedicated to developing and commercializing novel protein therapeutics for the treatment of metabolic diseases. The company’s innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream. Alnara’s lead product is liprotamase, a novel, non-porcine pancreatic enzyme replacement therapy, which has completed Phase 3 clinical development in collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. Alnara was co-founded in 2008 by Alexey Margolin, Rich Aldrich and Christoph Westphal and sold to Eli Lilly in 2010 for $180M upfront.

Companies Founded by Members of the Longwood Team

Axial Biotherapeutics Ovascience Flex Pharma
ALNARA Pharmaceuticals Sirtris Pharmaceuticals Momenta
CoNCERT Pharmaceuticals Alnylam Pharmaceuticals Acceleron Verastem